Novartis to expand gene therapy pipeline with acquisition of AveXis for $8.7 billion – Chemical & Engineering News
Zacks.com |
Novartis to expand gene therapy pipeline with acquisition of AveXis for $8.7 billion
Chemical & Engineering News Novartis plans to acquire the neurological gene therapy firm AveXis for $8.7 billion. The purchase will bolster the Swiss giant's standing as a big pharma leader in the emerging gene therapy field. AveXis's leading drug candidate is its gene therapy to … Gene Therapy in Limelight on Novartis Deal: 3 Stocks in Focus GSK Signs Strategic Agreement To Transfer Rare Disease Gene … Orchard Therapeutics to buy GSK's rare disease gene therapy portfolio |
